NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Impax Laboratories, Inc. (“Impax” or the “Company”) (NasdaqGS:IPXL) common stock between May 20, 2013 and July 28, 2014.
For more information, click here: http://zlk.9nl.com/impax-laboratories.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the quality control at the Company’s Taiwan production facility.
On July 29, 2014, Impax announced that the FDA had completed an inspection of the Company’s Taiwan facility. Based on the FDA’s inspection, the FDA issued a Form 483 stating that it had found “ten inspectional observations”, or deficiencies, at the Taiwan facility.
If you suffered a loss in Impax you have until October 13, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/impax-laboratories.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.